ArticleThe journal of vascular access2024
Evaluation of venocutaneous fistula as vascular access for hemodialysis: Examination of 46 limbs of 40 patients.
Article in The journal of vascular access, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 3 citations in OpenAlex.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionWe have previously evaluated the usefulness of venocutaneous fistula (VCF), also called "dermatorrhea." VCF is a technique of blood removal/return by advancing a dialysis cannula to the femoral vein for each hemodialysis session using a fistula created between the great saphenous vein and skin.
methodsIn this study, we evaluated 46 limbs of 40 patients for whom VCF was created at our hospital between May 2017 and April 2022. In all the patients, it was difficult to construct an arteriovenous fistula or arteriovenous graft because of the general/vascular conditions. The usefulness of this method was evaluated based on the results of dialysis treatment after fistula creation and the use of fistula.
resultsFundamental evaluation confirmed the progression of vascular wall thickening over time. During clinical review, no serious complications were found in any patient during or after fistula creation surgery. The infection rate was 0.30/1000 days of fistula maintenance. Secondary patency rates by the Kaplan-Meier method were 87.0% at 1 year and 42.6% at 3 years.
conclusionThis method has demonstrated a good patency rate, low infection rate, and seems to be a potentially useful alternative in patients in whom it is difficult to establish vascular access.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.